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Abstract: Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein
family, can be phosphorylated by receptor-associated Janus kinases (JAKs) in response to stimulation
by cytokines and growth factors. It forms homo- or heterodimers that can translocate to the cell
nucleus where they act as transcription activators. Constitutive activation of STAT3 has been found
to be associated with initiation and progression of various cancers. It can exert proliferative as well
as anti-apoptotic effects. This review focuses on the role of STAT3 in pathogenesis i.e., proliferation,
differentiation, migration, and apoptosis of hematological malignancies viz. leukemia, lymphoma
and myeloma, and briefly highlights the potential therapeutic approaches developed against STAT3
activation pathway.
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1. Introduction
Signal Transducers and Activators of Transcription (STATs), were first discovered in 1994
and found to be involved in interferon (IFN)-triggered transcription regulation [1–3]. To date,
seven different STAT proteins, namely STAT1, -2, -3, -4, -5a, -5b, and -6, have been discovered in
mammalian cells [2–5]. The STAT family proteins transduce intracellular and extracellular signals that
mediate multiple cellular functions including those related to survival, growth and proliferation, and
angiogenesis [6,7]. STAT family members are generally localized in the cytoplasmic compartment of
the cell, in an inactive state, either as monomers or as latent (unphosphorylated) dimers [8] that can
be activated by various stimuli such as cytokines and growth factors [9–11]. STATs are activated by
phosphorylation on tyrosine by Janus kinases (JAKs), Src family members, as well as growth factor
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receptors such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor
(PDGFR) [1,10,12]. The dimer thereafter enters the nucleus via interaction with importins and can bind
target genes [7].
2. Domain Structure and Signaling Cascade of STAT3
STAT3 is an important member of STAT family that regulates gene transcription by relaying signals
from activated plasma membrane receptors to the nucleus in response to various stimuli [13,14].
2.1. Structure of STAT3
The structure of the STAT3 molecule has several distinct functional domains (Figure 1):
• The N-terminal domain—composed of an oligomerization and a coiled-coil domain.
• The DNA-binding domain—that can recognize a specific molecular motif in the DNA.
• A linker domain.
• The Src homology 2 (SH2) domain—important for the formation of dimers; phospho-tyrosine 705
is important for this dimerization.
• The C-terminal transactivation domain—This domain differs between the α and β isoforms,
with the β form having a unique truncated C-terminal sequence. STAT3 protein also has a Ser
727 phosphorylation site, which though less studied than Tyr 705, is important for regulating
STAT3 activation by serine/threonine kinases such as the MAPKs (mitogen-activated protein
kinases) [15].
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phosphorylation of tyrosine residue at 705 by either receptor tyrosine kinases (RTK) such as EGFR, 
PDGFR, fibroblast growth factor receptor (FGFR), insulin-like growth factor receptor (IGFR) or 
receptor associated kinases such as JAK, and non-receptor tyrosine kinases like Src and Abl [18,19]. 
Ligation of these cell surface receptors causes stimulation of either: (1) intrinsic tyrosine kinase 
Figure 1. The molecular structure of the two STAT3 isoforms. The STAT3 molecule consists of several
distinct domains:(i) the N-terminal domain containing an oligomerization and a coiled-coil domain,
(ii) the DNA-binding domain, (iii) the linker domain, (iv) the Src homology 2 (SH2) domain, and (v) the
C-terminal Transactivation domain (TAD). STAT3α is the full-length STAT3 protein, with a TAD at the
C terminal that has a serine residue at position 727. STAT3β is the truncated STAT3 protein, without
the TAD.
2.2. STAT3 Signaling Cascade
STAT3, activated by phosphorylation, is a downstream target of several plasma membrane surface
receptors that can be activated by a plethora of soluble mediators, including interleukins (IL-2, I-L3,
IL-5, Il-6-IL-7, IL-9-IL11), other cytokines (G-CSF, EGF, PDGF), and several hormones (growth hormone,
prolactin, leptin) [16,17]. The activation of protein is brough about by phosphorylation of tyrosine
residue at 705 by either receptor tyrosine kinases (RTK) such as EGFR, PDGFR, fibroblast growth factor
receptor (FGFR), insulin-like growth factor receptor (IGFR) or receptor associated kinases such as JAK,
and non-receptor tyrosine kinases like Src and Abl [18,19]. Ligation of these cell surface receptors causes
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stimulation of either: (1) intrinsic tyrosine kinase activity or, (2) receptor chain aggregation and thereby
kinase activation (Figure 2). Although STAT3 dimerization is usually depicted after phosphorylation,
increasing evidences suggest the possibility of an existence of preformed latent STAT3 dimers. The Y705
phosphorylation induces the activation of these latent STAT3 dimers [8,20]. The dimers, both latent
and activated can shuttle between nucleus and cytoplasm. Latent or unphosphorylated dimers
shuttle via nucleoporins Nup 153 and 214 whereas, the translocation of activated STATs occurs via
interaction of nuclear localization signals (sequence motifs present on surface of STAT molecules) with
importins. The phosphorylated STAT3 dimer can then bind to the STAT consensus sequence to trigger
transcription of various downstream genes [21–24].
S727 phosphorylation in STAT3α isoform, necessary for activation, also seems to have an intrinsic
regulation mechanism for limiting STAT3 activation through dephosphorylation of Y705 by the
nuclear TC45 phosphatase [15]. STAT3β, though lacking the TAD, not only modulates transcription
of various genes but can also regulate the activity of α isoform [25]. Apart from this, three other
mechanisms negatively regulate STAT3 signaling: (1) Suppressor Of Cytokine Signaling (SOCS) family
by either direct inhibition of JAK activity (SOCS1 and SOCS3) or by competing with STAT-SH2
domains for phosphorylation by upstream kinases [26]; (2) Protein Inhibitor of Activated STATs
(PIAS) by preventing STAT3 from binding to DNA; and (3) Protein tyrosine phosphatases (PTP) such
as Src homology region 2 domain- containing phosphatase 1 and 2 (SHP1, SHP2), Receptor-type
tyrosine-protein phosphatase T and delta (PTPRT, PTPRD) by dephosphorylating STAT3 and thereby
deactivating it [27–29].
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Figure 2. A schematic representation of STAT3 signaling cascade. STAT proteins are present in
an inactive (unphosphorylated latent dimers) form in the cytoplasm. Upon ligand binding, the
receptors dimerize to recruit upstream JAK/Src kinases. Phosphorylated tyrosine residues on the
receptors provide a docking site to STATs and bring about their phosphorylation and activation.
Phosphory ted STATs upon translocation to nucleus bind onto the consensus sequence and thereby
regulate gene transcription.
3. Role of STAT3 in Tumorigenesis: Solid and Hematological Tumors
STAT3 was first exhibited to play a role in cancer growth by Yu et al. in 1995, whose study
suggested that the STAT3 activation can lead to regulation of oncogene expression [30]. Since then
aberrant STAT3 expression has documented in squamous cell carcinoma of the head and neck and other
solid tumors; and more recently, in haematologic malignancies [31–33]. Constitutively active STAT3
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has been established to trigger deregulated gene transcription where the gene products consequently
promote tumor progression. Altogether, STAT3 and its downstream target genes not only promote
proliferation (Cyclin D1, c-Myc), survival (Bcl-2, survivin, Bcl-xL), angiogenesis (VEGF, HIF1α), and
metastasis (MMPs), but also inhibit anti-tumor immune responses [3,34]. Conversely, interruption
of STAT3 activation in the cultured cells has been found to reverse these effects [3]. Moreover,
abrogation of STAT3 signalling has also exhibited tumor growth impairment and induction of apoptosis
in preclinical models [35,36]. Collectively, studies have shown that close to 70% of all solid and
hematological tumors exhibit aberrant STAT3 expression and/or activation [7,31], thus indicating its
pivotal role in tumorigenesis.
3.1. Role of STAT3 in Leukaemia
STAT3 has an important part in promoting leukemogenesis in hematopoietic stem cells.
Its overexpression has been seen in malignant hematopoietic stem cells (HSCs) in Acute Myeloid
Leukemia (AML) and Myelodysplastic syndrome MDS, thus insinuating that STAT3 plays a crucial
role in the development of malignancies [37]. Constitutive phosphorylation and activation of STATs
have been found in several leukemias [38,39] including AML [40], acute promyelocytic leukemia [41],
acute lymphoblastic leukemia (ALL) [42], chronic lymphocytic leukemia (CLL) [43], and chronic
myelogenous leukemia (CML) [40].
STAT3 has been shown to play a critical function in promoting tumor growth, increasing survival
of cancerous cells, promoting resistance to chemotherapy, and linked with an increased likelihood of
AML relapse in patients [32,44]. The SH2 domain of STAT3 has been found to be mutated in patients
with large granular lymphocytic leukemia as well as other types of leukemias, thus indicating that
anomalous STAT3 signaling may be underlying the pathogenesis of these diseases [45,46]. In 2014,
Shastri et al. revealed that patients with increased STAT3 expression in HSCs were associated with a
median survival of 2.6 years, while patients with lower STAT3 expression were observed to have a
median survival of 5.8 years [47].
3.2. Role of STAT3 in Lymphoma
Lymphoma is defined as the solid tumor of lymphocytes and can be broadly classified into two
categories: Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lymphomas (NHL) [48]. Gene expression
profiling and genomic sequence studies clearly implicate inappropriate activation of the JAK/STAT
signaling in the pathogenesis of a number of lymphoma sub-types, including diffuse large B-cell
lymphoma, HL, and primary mediastinal B-cell lymphoma [49].
Hodgkin’s lymphoma (HL) manifests constitutive activation of the JAK-STAT signaling pathway
in the neoplastic cells which, in classical HL, are called Hodgkin’s Reed–Sternberg (HRS) cells [36,50].
Constitutive phosphorylation of STAT1 and STAT3 has been found in several HL cell lines, as well as
primary HRS cells [51,52], leading to inappropriate expression of downstream genes such as Bcl-2 and
Bcl-xL; that have been implicated in cell survival and decreased susceptibility to apoptosis [53]. Also,
studies have shown that abrogation of the JAK/STAT pathway can induce cell-arrest and apoptosis
in vitro [53], inhibit tumor growth, achieve tumor elimination with significantly improved survival
in murine models of human HL [54], and can significantly improve progression-free survival time
specifically in patients with relapsed or treatment refractory HL [55].
NHL make up around 90% of all malignant lymphomas [56] and are generally classified according
to their origin, that is either B-cell NHL or T/NK-cell NHL [57]. In a recent study, Zhang et al.
have indicated that JNK and JAK/STAT pathways could stimulate cell proliferation and xenograft
growth in various NHL cell lines and patient derived samples by dysregulating the expression of
Insulin Enhancer Binding Protein 1 (ISL-1). The study also demonstrated that p-STAT3/p-c-Jun/ISL-1
formed a transcriptional complex that could bind directly to the ISL-1 promoter, causing its aberrant
expression [57]. Involvement of the STAT3 oncogene has also been reported in diffuse large B-cell
lymphoma (DLBCL) [58] and inhibition of STAT3 by targeted oligonucleotides have been shown to
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exert a therapeutic effect against human DLBCL xenotransplants in nude mice and to inhibit their
growth by a direct cytotoxic/cytostatic effect [59]. In T-cell lymphomas such as primary cutaneous
T-cell lymphomas (CTCL) and anaplastic large T-cell lymphoma (ALCL), both STAT3 and STAT5 are
deregulated, and the targeting these two proteins can inhibit tumor pathogenesis in vitro [60].
3.3. Role of STAT3 in Multiple Myeloma (MM)
Multiple myeloma (MM) is the second most common hematological malignancy, marked
by an accumulation of abnormal clonal plasma cells in the bone marrow [61]. Several major
signalling pathways have been implicated in the pathogenesis of MM including the JAK-STAT3,
PI3K/Akt/mTOR, and NF-κB pathways [62,63], wherein STAT3 might be constitutively active or
may be activated by the interleukin-6(IL-6)-JAK-STAT3 axis in MM [64]. STAT3 activation has been
reported to contribute to MM progression both directly by upregulating survival and anti-apoptotic
target genes [65], as well as indirectly by activating myeloid derived suppressor-cells (MDSCs) in the
bone marrow (BM) microenvironment, which causes T-cell suppression (immunosuppression) and
facilitates tumor progression [66]. Also, Jung et al. showed that phosphotyrosine-STAT3 expression is
correlated with poor prognosis and survival in MM patients [67]. Recent studies have implied that
inhibition of STAT3 signalling can inhibit tumor growth, re-sensitize them to therapy, and induce
apoptosis under both in vitro [68,69] and in vivo [70] conditions.
4. STAT3 as an Anti-Cancer Target and Selected Inhibition Strategies in Hematological
Malignancies
As discussed above, most hematological malignancies manifest elevated levels of constitutively
activated STAT3 and enhanced downstream transcriptional profiles in accordance with STAT3
regulated genes [13,14,71,72]. Tumor cell lines with constitutively activated STAT3 are dependent on
its sustained activation, a phenomenon that has been termed “oncogene addiction” [14]. Although
STAT3 activity has been shown to be imperative for embryonic development [17], it might be not be
indispensable for normal or non-transformed cells and tissues [13,14], thereby making it a potential
target for novel therapeutic development. Also, on a molecular structure level, STAT3, unlike other
transcription factors, has unique and different domains (as described above). These sites present
potential targets to modulate or inhibit STAT3 activation using multiple strategies [73]. Also, the
findings that a variety of mechanisms may be involved in inappropriate activation of this pathway
(Table 1), suggest its importance in hematological malignancies and, thus, make it an attractive target
for therapeutic intervention [21,74–84].
Table 1. Selected molecular mechanisms of aberrant activation of STAT3 in hematological malignancies.
Hematological Malignancy Subtype(s) Activation Mechanism(s) References
Acute Leukaemias ALL
BCR/abl fusion protein [76]
TEL-JAK2 fusion protein [77]
AML
Aberrant exogenous cytokine signaling [75]
Constitutive Protein Tyrosine Kinases (PTK)
activation without exposure to exogenous cytokines [75]
Activating STAT3 mutations [21]
Hypermethylation, hence, silencing of negative
regulators of STAT3 (PIAS3, SOCS3 and PTP) [21]
Chronic Leukemias CLL Casein Kinase2(CK2)-B cell linker (BLNK)-CD5complex causes constitutive phosphorylation [79]
CML JAK activation by bone marrow microenvironment [78]
Lymphomas HL
Activating mutations in JAK1 and STAT3 [80]
Autocrine secretion of IL13 by HRS cells [82]
NHL Autocrine and paracrine secretion of IL6 and IL13 [81,83]
Multiple Myeloma -
Autocrine and paracrine secretion of IL6 and
subsequent activation of JAK1 [62]
Overexpression and hyperactivation of CK2 [84]
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4.1. Strategies for STAT3 Inhibition
Broadly, two strategies can be employed for STAT3: (1) Direct inhibition and (2) Indirect inhibition
(Figure 3). Various targeted therapeutics have been developed based on one or more of these strategies.
Few selected pharmacological agents targeted at inhibiting the STAT3 signaling cascade for treating
various hematological malignancies are discussed in the following sections. The inhibitors may be
natural or synthetic compounds, including small molecules and nucleotides [85]. Some of the inhibitors
have also entered clinical trials for treatment or management of hematological malignancies and are
reviewed briefly in Table 2.
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4.1.1. Selected Natural Compounds as Exa l f ST T3 Signaling Inhibitors
Bavachin
Bavachin is a plant estrogen-like compound purified from plants such as Psoralea corylifolia.
Besides its estrogen-like activities, it has also demonstrated anti-tumor and anti-bacterial effects [86].
It has been shown that bavachin abated the viability of MM cell lines in a time- as well as
concentration-dependent fashion. Additionally, it also interrupted NF-κB and STAT3 phosphorylation.
Moreover, it also upregulated the expression of p53 as well as NOXA and downregulated that of XIAP,
survivin, Bcl-xL, and Bcl-2 proteins. Bavachin further impelled apoptosis by caspase-3/9 activation
and decrease the mitochondrial membrane poten ial. The comp und also exhibited tumor-specific
activity as the viability of normal cells was not affected [69].
Butein
Butein is a tetrahydroxychalcone derived from plants related to cashews. It has been demonstrated
to have a STAT3 inhibitory effect in various cell types including multiple myeloma (MM) cells.
Deterioration of both constitutive and inducible STAT3 activation in MM cells by butein is shown to
be mediated through the interruption of the upstream kinases c-Src and JAK 1&2 [87,88]. Butein was
also able to act synergistically with thalidomide and bortezomib, the two first line chemotherapeutic
agents for the treatment of MM, in inducing apoptosis in tumor cells. Many previous studies have
shown that butein is efficacious at a low drug concentration in murine xenograft models [89].
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Celastrol
Derived from the plant Tripterygium wilfordii, celastrol has been used in traditional Chinese
medicine since time immemorial. In the modern context, it has been demonstrated to exert anti-cancer
effects in various cancer models such as MM, AML, and hepatocellular carcinoma [68,90,91]. Celastrol
suppressed constitutive as well as inducible STAT3 activation in MM cells, and the effect has been
attributed to inhibition of c-Src and JAK2 activation. This abrogation induced apoptosis, lead to
an increase in the aggregation of cells in the sub-G1 phase, and activation of caspase-3, thereby
inducing cell death [68]. It has been also demonstrated that celastrol abates the growth of t(8:21) AML
cells by activating both extrinsic and intrinsic apoptotic pathways. Additionally, celastrol decreases
the expression of AML1-ETO and C-KIT at both transcriptional and translational levels, leading to
suppression of AKT, STAT3, and Erk1/2 activation and their downstream signaling [90]. However,
future studies in appropriate preclinical models are required to further elucidate the anti-cancer effects
of celastrol in vivo and examine its clinical toxicology/efficacy.
Cucurbitacins
Cucurbitacins are an imperative part of herbs used in many traditional Chinese medicines [92]
and have been shown to possess multiple and varied biological and medicinal properties ranging
from anti-inflammatory to anti-microbial [93]. The inhibitory effect of cucurbitacin B on STAT3 was
examined in the leukemia cell line K562. Following treatment with cucurbitacin B in nanomolar doses,
growth inhibition and apoptosis in these leukemic cells followed a G2/M cell cycle arrest. The cells
exhibited inhibition of STAT3 phosphorylation in a dose-dependent manner. However, the exact
mechanism of STAT3 abrogation in these cell lines remains unclear, although diverse molecules have
been found to mediate STAT3 suppressive effects of cucurbitacin B in other solid tumors [92,94].
Guggulsterone (GS)
The anti-leukemic effects of GS was initially reported by Samudio et al. [95] when they
investigated the anti-cancer effects of three pregnadienedione steroidal molecules (i.e., cis-GS, trans-GS,
and 16-dehydroprogesterone) in cultured leukemia cells and primary leukemic blast cells [95].
They reported that the treatment of HL-60 leukemia and U937 lymphoma cell lines with these
compounds resulted in caspase-independent apoptosis and a reduction in cell proliferation. All the
compounds were shown to induce generation reactive oxygen species (ROS), which could be one
possible pathway for apoptosis induction. Furthermore, the compounds caused the degradation of
constitutive extracellular signal-regulated kinase mediated phosphorylation of STAT3 [95]. The study
by Shishodia et al. [25] observed that the treatment of leukemia, myeloma, and melanoma cell lines with
GS decreased cell proliferation and caused a reduction in levels of cyclin D1 and cdc2. They also found
an increased expression of p21 and p27 proteins along with induction of apoptosis by activation of
PARP cleavage [25]. Another study further demonstrated that GS inhibited the constitutive activation
of STAT3 in U266 myeloma cells in a dose- and time-dependent manner. In the same study, Ahn et al.
also showed that GS decreased STAT3 DNA binding activity and IL-6-induced STAT3 phosphorylation.
It was further determined using sodium pervanadate that GS could inhibit STAT3 activation by
inducing the increased expression of a protein tyrosine phosphatase SHP1. It was also shown that
GS treatment could significantly suppress the expression of proteins such as cyclin D1, Bcl-2, Bcl-xL,
Mcl-1, and VEGF in a time-dependent manner [96].
Honokiol (HNK)
Honokiol (HNK), a biphenolic small molecular weight natural product extracted from the bark
and leaves of Magnolia officinalis, is widely acknowledged as an antimicrobial and anti-inflammatory
in traditional Chinese medicinal practice [97]. In multiple studies the compound has been shown to
be effective against various hematological malignancies such as MM, T-cell leukemia, B- cell CLL,
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and AML [98–101]. HNK has been found to decrease the levels of phosphorylated STAT3 but does
not affect total STAT3 expression. It has been shown to exhibit this effect through SHP1 expression
upregulation. Additionally, HNK has been reported to inhibit transcriptional activity of STAT3, reduce
its nuclear translocation, and decrease the expression of STAT3 regulated genes. The knockdown of
SHP1 by small hairpin RNA (shRNA) or its inhibition with pervanadate, abolished the HNK-induced
STAT3 inhibition, indicating that HNK may act via SHP1 regulation. Furthermore, HNK upregulated
the expression of transcription factor PU 1, which reportedly can activate the expression of SHP1.
PU 1 knockdown caused a reversal of HNK-induced upregulation of SHP1 and inactivation of STAT3
signaling. A similar increased expression of PU 1 and SHP1 in hematopoietic progenitors isolated
from patients with AML was observed following HNK treatment ex vivo [99]. HNK was also able
to induce the degradation of AML1-ETO in leukemic cell lines and primary AML blast cells having
t(8;21) translocation. Interestingly, HNK also augmented the expression of UbcH8, an E2-conjugase for
the degradation of AML1-ETO, by causing acetylation of histones in its promoter region [102].
Withaferin A
Withaferin A (WFA) is isolated from the plant Withania somnifera and shown to have
antiproliferative properties in several cancer types. It has also been demonstrated to have other
medicinal effects such as anti-inflammatory, anti-oxidant, and cardiovascular protection [103]. In the
context of hematological malignancies, the compound has been shown to be a direct inhibitor of STAT3
signaling as it binds to STAT3 near the Tyr 705 phosphorylation site, thereby preventing its dimerization
and hence its subsequent signaling cascade [104]. The findings warrant further investigation and
development of the drug for clinical trials.
4.1.2. Synthetic Inhibitors
Natural compounds have demonstrated promising effects in laboratory settings; however, it
would take considerable time for them to reach clinics for widespread patient use. Although these
compounds have promising low toxicity profiles, they face challenges such as specificity of targets,
potency and efficacy, and their mechanisms of action being undefined or understudied. However,
there are available a host of chemically synthesized molecules that exhibit promising STAT3 inhibiting
activity and, in many cases, can abrogate tumor growth. Here, we describe some of these synthetic
molecules with relevance to their use in hematological malignancies and their ability to act via direct
or indirect STAT3 inhibition.
Direct Inhibitors of STAT3 Activation
Direct inhibitors, as the name suggests, interact directly with the STAT3 domains to antagonize
STAT3 activation. These small molecules mainly interact with either the amino-terminal domain,
SH2 domain, or DNA-binding carboxy terminal domain of STAT3 molecules. The compounds
showing promising activity in targeting STAT3 in hematological malignancies include PY*LKTK,
PY*L, AY*L [105], and ISS 610 [106], which are essentially small molecule peptidomimetics that interact
with the SH2 domain, thereby preventing STAT dimerization and subsequent nuclear translocation
and transcription. Another class of direct inhibitors being used are the G-quartets (guanosine-rich
oligodeoxynucleotides) and decoy oligonucleotides. These guanosine-rich oligodeoxynucleotides were
originally identified at the 3′ end of telomeres, where they were found to inhibit telomerase activity,
and form intra- and inter-molecular four-stranded structures. These structures engage with the DNA
binding domain of STAT3 and block protein–DNA binding. For example, molecule T40214 has been
found to be a promising candidate in ALL [107]. Decoy nucleotides also work in a similar fashion as
they carry the consensus STAT-binding sequences, thereby preventing the protein from binding to the
STAT3 response element within the promoter [59]. Oligonucleotide mediated inhibition of STAT3 has
also been achieved by using antisense oligonucleotides against STAT3 mRNA. A prime example of this
class of therapeutics is AZD 9150 which exhibited antitumor activity in treatment refractory lymphoma
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patients in phase I study [108]. Another class of molecules using direct interaction with STAT3 proteins
are chemotherapeutics. The novel platinum (IV) compound IS3 295 has been shown to irreversibly
bind to the DNA binding domain of STAT3 in both its active and inactive form, and hence, preventing
STAT3 from binding to DNA. The compound also exhibited suppression of STAT3 induced genes
Bcl-xL and cyclin D1 [109]. More direct STAT3 inhibitors are in development, such as the dual-function
molecule CpG-STAT3dODN, which consists of a TLR9 (Toll like receptor) agonist (CpG7909) and a
STAT3 inhibitor, high-affinity decoy oligodeoxynucleotide for B-cell lymphoma immunotherapy [59].
Indirect Inhibitors
STAT3 is a multistep signaling cascade involving a multitude of components. This provides
an opportunity for the development of compounds that can interact with other constituents of the
pathway and thus abrogate STAT3 activity in a defined manner. One of the foremost approaches to
indirect STAT3 inhibition is receptor antagonism. As STATs are downstream to several cytokine and
growth receptors, especially in MM and leukemias, monoclonal antibodies blocking these receptors
represent a promising choice. As a proof of concept, the chimeric antibody rituximab has shown
inhibition of constitutive STAT3 activity by blocking the CD-20 receptor in Non-Hodgkin’s Lymphoma.
The blockage was demonstrated to downregulate IL-10, leading to STAT3 inhibition [110].
In MM, JAKs can be activated by IL-6 present in the bone marrow micro-environment. This leads
to recruitment of two gp130 signal–transducing subunits to the receptor complex; consequently,
gp130-associated JAKs (i.e., JAK1, JAK2, and Tyk2) become activated to provide docking sites for
STAT3 [111]. Therefore, specific tyrosine kinase inhibitors have caught focal attention as agents for
disruption of STAT activation. Selective and specific cessation of JAK2 activity has been demonstrated
using AG490 and its congeners LS-104 [112], CEP701, and ICNB18424, and has been shown to inhibit
the growth of leukemia cells both in vitro and in vivo [113,114]. LS-104 is currently in phase II
clinical trials for the treatment of ALL and has shown promising STAT3 inhibition in vitro in FLT3
positive AML [113,115]. NCB1824, a small-molecule inhibitor of both JAK1 and JAK2, suppresses
levels of phosphorylated STAT3 in subjects with wild-type JAK2 or with the gain-of-function V617F
JAK2 mutation, as revealed in a phase 1–2 clinical trial of myelofibrosis patients. Another synthetic
compound INCB20 potently disrupts the activation of all members of the JAK family, and thus blocks
the IL-6 mediated progression of MM. It also blocks SH-2 phosphorylation, thus abrogating cytokine
mediated dexamethasone resistance [116].
Other than JAK activation, elevated levels and/or kinase activity of Src and other growth factor
receptors have been indicated in several cancers, causing activation of STAT3. These also make
important potential targets to check STAT3 activity. One such molecule is Dasatinib, which can inhibit
SFK and BCR/ABL activation and has been approved for use as second line treatment in patients with
chronic myelogenous leukemia and also for Philadelphia chromosome–positive ALL [38]. Although
they are a druggable components of the STAT3 cascade, the relatively modest response rates of tumors
to therapeutic agents that target the EGFR, JAKs, and SFKs illustrate that the inhibition of single
pathways may be insufficient to completely block the aberrant activation of STAT3 [85].
Targeting STAT nuclear translocation is yet another potential approach to develop efficacious
anti-cancer drugs. The activity of phosphorylated STAT3 as a DNA-binding transcription factor
depends upon the trafficking of homodimers from cytosol and into the nucleus [117]. One such
compound, Selinexor, has exhibited potential clinical activity in AML and MM [118]. More such
inhibitors are in the pipeline to be further examined and understood but they present a promising
class of STAT3 inhibitors.
STAT3 proteins exhibit negative regulation by 3 major protein families: (1) Phosphotyrosine
phosphatase (PTP) which regulates its activity by dephosphorylating upstream kinases [119]; (2) PIAS,
and (3) SOCS, which are negative regulators of STAT3 signaling [120,121]. Specific demethylation
agents seem to be an interesting class of STAT3 regulators, since hypermethylation can silence these
protein regulators in AML.
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Table 2. Selective STAT3 inhibitors in clinical trials for hematological malignancies.
Inhibitor Indication Status References
Dasatinib (Tyrosine Kinase
Inhibitor) ALL, CML FDA approved, specifically for Ph+ cases [122]
Imatinib (Bcr-Abl Tyrosine Kinase
Inhibitor) CML, ALL FDA approved, specifically for Ph+ cases [123]
Ruxolitinib (JAK 1&2 inhibitor)
Myeloproliferative
neoplasms
FDA approved for Myelofibrosis and as second
line treatment for Polycythemia vera [124]
AML Phase I/II trial terminated due to lack of efficacy [125]
Pyrimethamine (Direct STAT3
SH2 domain inhibitor) CLL Phase I/II clinical trials [126]
AZD 9150 (STAT3 Antisense
oligonucleotide) Lymphoma Phase I dose escalation study completed [108]
OPB 31121 (STAT3 SH2 domain
inhibitor) MM, NHL Leukemia
Trial terminated due to high toxicity and poor
pharmacokinetics [126]
OPB 51602 (STAT3 SH2 domain
inhibitor) MM, AML NHL, CML
Trial terminated due to inefficacy in
hematological malignancies [126]
5. Conclusions and Future Perspectives
Several hallmarks of cancer, such as uncontrolled cellular proliferation, invasion/metastasis,
and resistance to apoptosis, are associated with dysregulated STAT signaling. In the context of
hematological malignancies, aberrant STAT3 activation becomes an even more important factor in
tumor pathogenesis due to the constant presence of cytokines and growth factors in the bone marrow
microenvironment. Although not the only transcription factor involved in tumorigenesis, its inhibition
has been shown to prevent malignant transformation in leukemias and lymphomas. Elucidation of
multifaceted STAT3 signaling cascade using multi-omics approaches can lead to deeper understanding
of its pathological role in the development of malignancies and their progression.
In conclusion, it can be reconciled that STAT3 has been validated as a druggable target and
important pathway in cancer therapeutics. Our lab and other pharma-oncology groups are working
with various classes of pharmacological blockers of STAT3 signaling, and important advancements
have been made in recent years to develop clinically relevant drug candidates for STAT3 inhibition.
Although it remains a challenge to develop a truly potent and specific STAT3 inhibitor, the current
compounds can serve as great leads to develop better and efficacious anticancer therapies.
Author Contributions: A.P.K., W.J.C. and G.S. conceived the project; L.A. wrote the article, F.A. edited
the manuscript.
Funding: This work was supported by Ministry of Education Tier 1 grant to G. Sethi. APK was supported by
grants from National Medical Research Council of Singapore and by the National Research Foundation Singapore
and the Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science
Institute of Singapore, National University of Singapore.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Darnell, J.E., Jr. The JAK-STAT pathway: Summary of initial studies and recent advances. Recent Prog. Horm.
Res. 1996, 51, 391–403. [PubMed]
2. Siveen, K.S.; Nguyen, A.H.; Lee, J.H.; Li, F.; Singh, S.S.; Kumar, A.P.; Low, G.; Jha, S.; Tergaonkar, V.; Ahn, K.S.;
et al. Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol
inhibits growth and induces apoptosis in hepatocellular carcinoma cells. Br. J. Cancer 2014, 111, 1327–1337.
[CrossRef] [PubMed]
3. Siveen, K.S.; Sikka, S.; Surana, R.; Dai, X.; Zhang, J.; Kumar, A.P.; Tan, B.K.H.; Sethi, G.; Bishayee, A. Targeting
the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Rev. Cancer 2014, 1845,
136–154. [CrossRef] [PubMed]
4. Ihle, J.N. The STAT family in cytokine signaling. Curr. Opin. Cell Biol. 2001, 13, 211–217. [CrossRef]
Cancers 2018, 10, 327 11 of 17
5. Subramaniam, A.; Shanmugam, M.K.; Ong, T.H.; Li, F.; Perumal, E.; Chen, L.; Vali, S.; Abbasi, T.; Kapoor, S.;
Ahn, K.S.; et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma
model by blocking activation of STAT3. Br. J. Pharmacol. 2013, 170, 807–821. [CrossRef] [PubMed]
6. Xiong, A.; Yang, Z.; Shen, Y.; Zhou, J.; Shen, Q. Transcription factor STAT3 as a novel molecular target for
cancer prevention. Cancers 2014, 6, 926–957. [CrossRef] [PubMed]
7. Fagard, R.; Metelev, V.; Souissi, I.; Baran-Marszak, F. STAT3 inhibitors for cancer therapy: Have all roads
been explored? Jakstat 2013, 2, e22882. [CrossRef] [PubMed]
8. Vogt, M.; Domoszlai, T.; Kleshchanok, D.; Lehmann, S.; Schmitt, A.; Poli, V.; Richtering, W.; Müller-Newen, G.
The role of the n-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. J. Cell
Sci. 2011, 124, 900–909. [CrossRef] [PubMed]
9. Braunstein, J.; Brutsaert, S.; Olson, R.; Schindler, C. STATs dimerize in the absence of phosphorylation. J. Biol.
Chem. 2003, 278, 34133–34140. [CrossRef] [PubMed]
10. Mohan, C.D.; Bharathkumar, H.; Bulusu, K.C.; Pandey, V.; Rangappa, S.; Fuchs, J.E.; Shanmugam, M.K.;
Dai, X.; Li, F.; Deivasigamani, A.; et al. Development of a novel azaspirane that targets the janus kinase-signal
transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
J. Biol. Chem. 2014, 289, 34296–34307. [CrossRef] [PubMed]
11. Dai, X.; Ahn Kwang, S.; Kim, C.; Siveen Kodappully, S.; Ong Tina, H.; Shanmugam Muthu, K.; Li, F.; Shi, J.;
Kumar Alan, P.; Wang Ling, Z.; et al. Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of
hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. Mol. Oncol.
2015, 9, 818–833. [CrossRef] [PubMed]
12. Santoni, M.; Massari, F.; Del Re, M.; Ciccarese, C.; Piva, F.; Principato, G. Investigational therapies targeting
signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opin. Investig. Drugs
2015, 1, 1–16. [CrossRef] [PubMed]
13. Leeman, R.J.; Lui, V.W.Y.; Grandis, J.R. STAT3 as a therapeutic target in head and neck cancer. Expert Opin.
Biol. Ther. 2006, 6, 231–241. [CrossRef] [PubMed]
14. Frank, D.A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007, 251, 199–210.
[CrossRef] [PubMed]
15. Wakahara, R.; Kunimoto, H.; Tanino, K.; Kojima, H.; Inoue, A.; Shintaku, H.; Nakajima, K. Phospho-Ser727
of STAT3 regulates STAT3 activity by enhancing dephosphorylation of phospho-Tyr705 largely through
TC45. Genes Cells 2012, 17, 132–145. [CrossRef] [PubMed]
16. Rane, S.G.; Reddy, E.P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21, 3334–3358.
[CrossRef] [PubMed]
17. Takeda, K.; Noguchi, K.; Shi, W.; Tanaka, T.; Matsumoto, M.; Yoshida, N.; Kishimoto, T.; Akira, S. Targeted
disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 1997, 94,
3801–3804. [CrossRef] [PubMed]
18. Hutchins, A.P.; Diez, D.; Miranda-Saavedra, D. Genomic and computational approaches to dissect the
mechanisms of STAT3’s universal and cell type-specific functions. Jakstat 2013, 2, e25097. [CrossRef]
[PubMed]
19. Mali, S.B. Review of STAT3 (signal transducers and activators of transcription) in head and neck cancer. Oral
Oncol. 2015, 51, 565–569. [CrossRef] [PubMed]
20. Hinde, E.; Pandzic, E.; Yang, Z.; Ng, I.H.; Jans, D.A.; Bogoyevitch, M.A.; Gratton, E.; Gaus, K. Quantifying
the dynamics of the oligomeric transcription factor STAT3 by pair correlation of molecular brightness.
Nat. Commun. 2016, 7, 11047. [CrossRef] [PubMed]
21. Bruserud, Ø.; Nepstad, I.; Hauge, M.; Hatfield, K.J.; Reikvam, H. STAT3 as a possible therapeutic target in
human malignancies: Lessons from acute myeloid leukemia. Expert Rev. Hematol. 2015, 8, 29–41. [CrossRef]
[PubMed]
22. Liu, L.; McBride, K.M.; Reich, N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and
mediated by importin-α3. Proc. Natl. Acad. Sci. USA 2005, 102, 8150–8155. [CrossRef] [PubMed]
23. Ma, J.; Cao, X. Regulation of STAT3 nuclear import by importin alpha5 and importin α 7 via two different
functional sequence elements. Cell. Signal. 2006, 18, 1117–1126. [CrossRef] [PubMed]
24. Reich, N.C.; Liu, L. Tracking STAT nuclear traffic. Nat. Rev. Immunol. 2006, 6, 602–612. [CrossRef] [PubMed]
Cancers 2018, 10, 327 12 of 17
25. Ng, I.H.; Ng, D.C.; Jans, D.A.; Bogoyevitch, M.A. Selective STAT3-α or -β expression reveals
spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes.
Biochem. J. 2012, 447, 125–136. [CrossRef] [PubMed]
26. Croker, B.A.; Kiu, H.; Nicholson, S.E. Socs regulation of the JAK/STAT signalling pathway. Semin. Cell Dev.
Biol. 2008, 19, 414–422. [CrossRef] [PubMed]
27. Junicho, A.; Matsuda, T.; Yamamoto, T.; Kishi, H.; Korkmaz, K.; Saatcioglu, F.; Fuse, H.; Muraguchi, A.
Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells.
Biochem. Biophys. Res. Commun. 2000, 278, 9–13. [CrossRef] [PubMed]
28. Li, J.; Beaulieu, D.R.; Paudel, H.; Barankov, R.; Bifano, T.G.; Mertz, J. Conjugate adaptive optics in widefield
microscopy with an extended-source wavefront sensor. Optica 2015, 2, 682–688. [CrossRef]
29. Johnson, D.E.; O’Keefe, R.A.; Grandis, J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev.
Clin. Oncol. 2018, 15, 234–248. [CrossRef] [PubMed]
30. Yu, C.L.; Meyer, D.J.; Campbell, G.S.; Larner, A.C.; Carter-Su, C.; Schwartz, J.; Jove, R. Enhanced
DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. Science
1995, 269, 81–83. [CrossRef] [PubMed]
31. Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological
tumors. Cell Res. 2008, 18, 254–267. [CrossRef] [PubMed]
32. Redell, M.S.; Ruiz, M.J.; Alonzo, T.A.; Gerbing, R.B.; Tweardy, D.J. STAT3 signaling in acute myeloid leukemia:
Ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule STAT3
inhibitor. Blood 2011, 117, 5701–5709. [CrossRef] [PubMed]
33. Yue, P.; Turkson, J. Targeting STAT3 in cancer: How successful are we? Expert Opin. Investig. Drugs 2009, 18,
45–56. [CrossRef] [PubMed]
34. Chai, E.Z.; Shanmugam, M.K.; Arfuso, F.; Dharmarajan, A.; Wang, C.; Kumar, A.P.; Samy, R.P.; Lim, L.H.;
Wang, L.; Goh, B.C.; et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol.
Ther. 2016, 162, 86–97. [CrossRef] [PubMed]
35. Huang, C.; Jiang, T.; Zhu, L.; Liu, J.; Cao, J.; Huang, K.J.; Qiu, Z.J. STAT3-targeting RNA interference inhibits
pancreatic cancer angiogenesis in vitro and in vivo. Int. J. Oncol. 2011, 38, 1637–1644. [PubMed]
36. Du, W.; Hong, J.; Wang, Y.C.; Zhang, Y.J.; Wang, P.; Su, W.Y.; Lin, Y.W.; Lu, R.; Zou, W.P.; Xiong, H.; et al.
Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway.
J. Cell. Mol. Med. 2012, 16, 1878–1888. [CrossRef] [PubMed]
37. Will, B.; Zhou, L.; Vogler, T.O.; Ben-Neriah, S.; Schinke, C.; Tamari, R.; Yu, Y.; Bhagat, T.D.; Bhattacharyya, S.;
Barreyro, L.; et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific
expansion and harbor genetic and epigenetic alterations. Blood 2012, 120, 2076–2086. [CrossRef] [PubMed]
38. Benekli, M.; Baumann, H.; Wetzler, M. Targeting signal transducer and activator of transcription signaling
pathway in leukemias. J. Clin. Oncol. 2009, 27, 4422–4432. [CrossRef] [PubMed]
39. Sternberg, D.W.; Gilliland, D.G. The role of signal transducer and activator of transcription factors in
leukemogenesis. J. Clin. Oncol. 2004, 22, 361–371. [CrossRef] [PubMed]
40. Munoz, J.; Dhillon, N.; Janku, F.; Watowich, S.S.; Hong, D.S. STAT3 inhibitors: Finding a home in lymphoma
and leukemia. Oncologist 2014, 19, 536–544. [CrossRef] [PubMed]
41. Dong, S.; Chen, S.J.; Tweardy, D.J. Cross-talk between retinoic acid and STAT3 signaling pathways in acute
promyelocytic leukemia. Leuk. Lymphoma 2003, 44, 2023–2029. [CrossRef] [PubMed]
42. Gouilleux-Gruart, V.; Gouilleux, F.; Desaint, C.; Claisse, J.F.; Capiod, J.C.; Delobel, J.; Weber-Nordt, R.;
Dusanter-Fourt, I.; Dreyfus, F.; Groner, B.; et al. STAT-related transcription factors are constitutively activated
in peripheral blood cells from acute leukemia patients. Blood 1996, 87, 1692–1697. [PubMed]
43. Frank, D.A.; Mahajan, S.; Ritz, J. B lymphocytes from patients with chronic lymphocytic leukemia contain
signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine
residues. J. Clin. Investig. 1997, 100, 3140–3148. [CrossRef] [PubMed]
44. Shastri, A.; Teixeira, M.; Bhattacharyya, S.; Ramachandra, N.; Lopez, R.; Ravipati, G.; Feld, J.; Dhar, Y.;
Bhagat, T.D.; Choudhary, G.; et al. Targeting MDS and AML stem cells with AZD-9150 mediated inhibition
of STAT3. Blood 2016, 128, 4314.
45. Koskela, H.L.M.; Eldfors, S.; Ellonen, P.; Van Adrichem, A.J.; Kuusanmäki, H.; Andersson, E.I.; Lagström, S.;
Clemente, M.J.; Olson, T.; Jalkanen, S.E.; et al. Somatic STAT3 mutations in large granular lymphocytic
leukemia. N. Engl. J. Med. 2012, 366, 1905–1913. [CrossRef] [PubMed]
Cancers 2018, 10, 327 13 of 17
46. Shahmarvand, N.; Nagy, A.; Shahryari, J.; Ohgami, R.S. Mutations in the signal transducer and activator of
transcription family of genes in cancer. Cancer Sci. 2018, 109, 926–933. [CrossRef] [PubMed]
47. Shastri, A.; Schinke, C.; Varshavsky Yanovsky, A.; Bhagat, T.D.; Giricz, O.; Barreyro, L.; Boultwood, J.;
Pellagati, A.; Yu, Y.; Brown, J.R.; et al. Targeting of MDS and AML stem cells via inhibition of STAT3 by
pyrimethamine. Blood 2014, 124, 3602.
48. Shankland, K.R.; Armitage, J.O.; Hancock, B.W. Non-Hodgkin lymphoma. Lancet 2012, 380, 848–857.
[CrossRef]
49. Scott, L.M.; Gandhi, M.K. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for
the development of new targeted therapies. Blood Rev. 2015, 29, 405–415. [CrossRef] [PubMed]
50. Kanzler, H.; Kuppers, R.; Hansmann, M.L.; Rajewsky, K. Hodgkin and reed-sternberg cells in Hodgkin’s
disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.
J. Exp. Med. 1996, 184, 1495–1505. [CrossRef] [PubMed]
51. Garcia, J.F.; Camacho, F.I.; Morente, M.; Fraga, M.; Montalban, C.; Alvaro, T.; Bellas, C.; Castano, A.; Diez, A.;
Flores, T.; et al. Hodgkin and reed-sternberg cells harbor alterations in the major tumor suppressor pathways
and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 2003, 101, 681–689. [CrossRef] [PubMed]
52. Kube, D.; Holtick, U.; Vockerodt, M.; Ahmadi, T.; Haier, B.; Behrmann, I.; Heinrich, P.C.; Diehl, V.; Tesch, H.
STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001, 98, 762–770. [CrossRef] [PubMed]
53. Mackenzie, G.G.; Queisser, N.; Wolfson, M.L.; Fraga, C.G.; Adamo, A.M.; Oteiza, P.I. Curcumin induces
cell-arrest and apoptosis in association with the inhibition of constitutively active NF-κB and STAT3 pathways
in Hodgkin’s lymphoma cells. Int. J. Cancer 2008, 123, 56–65. [CrossRef] [PubMed]
54. Ju, W.; Zhang, M.; Wilson, K.M.; Petrus, M.N.; Bamford, R.N.; Zhang, X.; Guha, R.; Ferrer, M.; Thomas, C.J.;
Waldmann, T.A. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or navitoclax in
a murine model of human Hodgkin’s lymphoma. Proc. Natl. Acad. Sci. USA 2016, 113, 1624–1629. [CrossRef]
[PubMed]
55. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.;
Millenson, M.M.; Cattry, D.; Freeman, G.J.; et al. PD-1 blockade with nivolumab in relapsed or refractory
Hodgkin’s lymphoma. N. Engl. J. Med. 2015, 372, 311–319. [CrossRef] [PubMed]
56. Ekstrom-Smedby, K. Epidemiology and etiology of Non-Hodgkin lymphoma—A review. Acta Oncol. 2006,
45, 258–271. [CrossRef] [PubMed]
57. Zhang, Q.; Yang, Z.; Jia, Z.; Liu, C.; Guo, C.; Lu, H.; Chen, P.; Ma, K.; Wang, W.; Zhou, C. ISL-1 is overexpressed
in Non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/pc-JUN/ISL-1
complex. Mol. Cancer 2014, 13, 181. [CrossRef] [PubMed]
58. Cabanillas, F. Non-Hodgkin’s lymphoma: The old and the new. Clin. Lymphoma Myeloma Leuk. 2011, 11,
S87–S90. [CrossRef] [PubMed]
59. Zhao, X.; Zhang, Z.; Moreira, D.; Su, Y.-L.; Won, H.; Adamus, T.; Dong, Z.; Liang, Y.; Yin, H.H.; Swiderski, P.;
et al. B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors. Mol. Ther.
2018, 26, 695–707. [CrossRef] [PubMed]
60. Mitchell, T.J.; John, S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.
Immunology 2005, 114, 301–312. [CrossRef] [PubMed]
61. Roodman, G.D. Pathogenesis of myeloma bone disease. Leukemia 2008, 23, 435–441. [CrossRef] [PubMed]
62. Hu, J.; Hu, W.X. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for
treatments. Cancer Lett. 2018, 414, 214–221. [CrossRef] [PubMed]
63. Podar, K.; Chauhan, D.; Anderson, K.C. Bone marrow microenvironment and the identification of new
targets for myeloma therapy. Leukemia 2008, 23, 10–24. [CrossRef] [PubMed]
64. Ramakrishnan, V.; Kimlinger, T.; Haug, J.; Timm, M.; Wellik, L.; Halling, T.; Pardanani, A.; Tefferi, A.;
Vincent Rajkumar, S.; Kumar, S. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple
myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am. J. Hematol. 2010, 85, 675–686.
[CrossRef] [PubMed]
65. Sansone, P.; Bromberg, J. Targeting the interleukin-6/JAK/STAT pathway in human malignancies. J. Clin.
Oncol. 2012, 30, 1005–1014. [CrossRef] [PubMed]
66. Wang, J.; De Veirman, K.; Faict, S.; Frassanito Maria, A.; Ribatti, D.; Vacca, A.; Menu, E. Multiple
myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis
and immunosuppression. J. Pathol. 2016, 239, 162–173. [CrossRef] [PubMed]
Cancers 2018, 10, 327 14 of 17
67. Jung, S.-H.; Ahn, S.-Y.; Choi, H.-W.; Shin, M.-G.; Lee, S.-S.; Yang, D.-H.; Ahn, J.-S.; Kim, Y.-K.; Kim, H.-J.;
Lee, J.-J. STAT3 expression is associated with poor survival in non-elderly adult patients with newly
diagnosed multiple myeloma. Blood Res. 2017, 52, 293–299. [CrossRef] [PubMed]
68. Kannaiyan, R.; Hay, H.S.; Rajendran, P.; Li, F.; Shanmugam, M.K.; Vali, S.; Abbasi, T.; Kapoor, S.; Sharma, A.;
Kumar, A.P.; et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation
of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol. 2011, 164,
1506–1521. [CrossRef] [PubMed]
69. Takeda, T.; Tsubaki, M.; Tomonari, Y.; Kawashima, K.; Itoh, T.; Imano, M.; Satou, T.; Nishida, S. Bavachin
induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B
and signal transducer and activator of transcription 3. Biomed. Pharmacother. 2018, 100, 486–494. [CrossRef]
[PubMed]
70. Hu, L.; Wu, H.; Li, B.; Song, D.; Yang, G.; Chen, G.; Xie, B.; Xu, Z.; Zhang, Y.; Yu, D.; et al. Dihydrocelastrol
inhibits multiple myeloma cell proliferation and promotes apoptosis through Erk1/2 and IL-6/STAT3
pathways in vitro and in vivo. Acta Biochim. Biophys. Sin. 2017, 49, 420–427. [CrossRef] [PubMed]
71. Aggarwal, B.B.; Kunnumakkara, A.B.; Harikumar, K.B.; Gupta, S.R.; Tharakan, S.T.; Koca, C.; Dey, S.;
Sung, B. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the
relationship? Ann. N. Y. Acad. Sci. 2009, 1171, 59–76. [CrossRef] [PubMed]
72. Jing, N.; Tweardy, D.J. Targeting STAT3 in cancer therapy. Anti-Cancer Drugs 2005, 16, 601–607. [CrossRef]
[PubMed]
73. Walker, S.R.; Frank, D.A. Screening approaches to generating STAT inhibitors: Allowing the hits to identify
the targets. Jakstat 2012, 1, 292–299. [CrossRef] [PubMed]
74. Lin, T.S.; Mahajan, S.; Frank, D.A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene
2000, 19, 2496–2504. [CrossRef] [PubMed]
75. Xia, Z.; Baer, M.R.; Block, A.W.; Baumann, H.; Wetzler, M. Expression of signal transducers and activators of
transcription proteins in acute myeloid leukemia blasts. Cancer Res. 1998, 58, 3173–3180. [PubMed]
76. Frank, D.A.; Varticovski, L. BCR/Abl leads to the constitutive activation of STAT proteins, and shares an
epitope with tyrosine phosphorylated STATs. Leukemia 1996, 10, 1724–1730. [PubMed]
77. Lacronique, V.; Boureux, A.; Valle, V.D.; Poirel, H.; Quang, C.T.; Mauchauffe, M.; Berthou, C.; Lessard, M.;
Berger, R.; Ghysdael, J.; et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Science 1997, 278, 1309–1312. [CrossRef] [PubMed]
78. Nair, R.R.; Tolentino, J.H.; Hazlehurst, L.A. Role of STAT3 in transformation and drug resistance in CML.
Front. Oncol. 2012, 2, 30. [CrossRef] [PubMed]
79. Rozovski, U.; Harris, D.M.; Li, P.; Liu, Z.; Jain, P.; Veletic, I.; Ferrajoli, A.; Burger, J.; O’Brien, S.; Bose, P.; et al.
Constitutive phosphorylation of STAT3 by the CK2-BLNK-CD5 complex. Mol. Cancer Res. 2017, 15, 610–618.
[CrossRef] [PubMed]
80. Tiacci, E.; Ladewig, E.; Schiavoni, G.; Penson, A.; Fortini, E.; Pettirossi, V.; Wang, Y.; Rosseto, A.; Venanzi, A.;
Vlasevska, S.; et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood
2018, 131, 2454–2465. [CrossRef] [PubMed]
81. Zhang, L.; Yang, J.; Qian, J.; Li, H.; Romaguera, J.E.; Kwak, L.W.; Wang, M.; Yi, Q. Role of the
microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.
Blood 2012, 120, 3783–3792. [CrossRef] [PubMed]
82. Skinnider, B.F.; Kapp, U.; Mak, T.W. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk.
Lymphoma 2002, 43, 1203–1210. [CrossRef] [PubMed]
83. Alas, S.; Bonavida, B. Inhibition of constitutive STAT3 activity sensitizes resistant Non-Hodgkin’s lymphoma
and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 2003, 9, 316–326.
[PubMed]
84. Piazza, F.; Manni, S.; Semenzato, G. Novel players in multiple myeloma pathogenesis: Role of protein kinases
CK2 and GSK3. Leuk. Res. 2013, 37, 221–227. [CrossRef] [PubMed]
85. Johnston, P.A.; Grandis, J.R. STAT3 signaling: Anticancer strategies and challenges. Mol. Interv. 2011, 11,
18–26. [CrossRef] [PubMed]
86. Park, J.; Kim, D.H.; Ahn, H.N.; Song, Y.S.; Lee, Y.J.; Ryu, J.H. Activation of estrogen receptor by bavachin
from Psoralea corylifolia. Biomol. Ther. 2012, 20, 183–188. [CrossRef] [PubMed]
Cancers 2018, 10, 327 15 of 17
87. Pandey, M.K.; Sung, B.; Ahn, K.S.; Aggarwal, B.B. Butein suppresses constitutive and inducible signal
transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through
the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol. 2009, 75, 525–533. [CrossRef]
[PubMed]
88. Padmavathi, G.; Rathnakaram, S.R.; Monisha, J.; Bordoloi, D.; Roy, N.K.; Kunnumakkara, A.B. Potential of
butein, a tetrahydroxychalcone to obliterate cancer. Phytomedicine 2015, 22, 1163–1171. [CrossRef] [PubMed]
89. Padmavathi, G.; Roy, N.K.; Bordoloi, D.; Arfuso, F.; Mishra, S.; Sethi, G.; Bishayee, A.; Kunnumakkara, A.B.
Butein in health and disease: A comprehensive review. Phytomedicine 2017, 25, 118–127. [CrossRef] [PubMed]
90. Yu, X.; Ruan, X.; Zhang, J.; Zhao, Q. Celastrol induces cell apoptosis and inhibits the expression of the
AML1-ETO/C-KIT oncoprotein in t (8;21) leukemia. Molecules 2016, 21, 574. [CrossRef] [PubMed]
91. Rajendran, P.; Li, F.; Shanmugam, M.K.; Kannaiyan, R.; Goh, J.N.; Wong, K.F.; Wang, W.; Khin, E.;
Tergaonkar, V.; Kumar, A.P.; et al. Celastrol suppresses growth and induces apoptosis of human
hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo.
Cancer Prev. Res. 2012, 5, 631–643. [CrossRef] [PubMed]
92. Chan, K.T.; Li, K.; Liu, S.L.; Chu, K.H.; Toh, M.; Xie, W.D. Cucurbitacin B inhibits STAT3 and the Raf/Mek/Erk
pathway in leukemia cell line K562. Cancer Lett. 2010, 289, 46–52. [CrossRef] [PubMed]
93. Chen, J.C.; Chiu, M.H.; Nie, R.L.; Cordell, G.A.; Qiu, S.X. Cucurbitacins and cucurbitane glycosides:
Structures and biological activities. Nat. Prod. Rep. 2005, 22, 386–399. [CrossRef] [PubMed]
94. Luca, C.; Daniela, B. STAT 3 as a target for cancer drug discovery. Curr. Med. Chem. 2008, 15, 834–843.
95. Samudio, I.; Konopleva, M.; Safe, S.; McQueen, T.; Andreeff, M. Guggulsterones induce apoptosis and
differentiation in acute myeloid leukemia: Identification of isomer-specific antileukemic activities of the
pregnadienedione structure. Mol. Cancer Ther. 2005, 4, 1982–1992. [CrossRef] [PubMed]
96. Ahn, K.S.; Sethi, G.; Sung, B.; Goel, A.; Ralhan, R.; Aggarwal, B.B. Guggulsterone, a farnesoid X receptor
antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine
phosphatase SHP-1. Cancer Res. 2008, 68, 4406–4415. [CrossRef] [PubMed]
97. Prasad, R.; Katiyar, S.K. Honokiol, an active compound of magnolia plant, inhibits growth, and progression
of cancers of different organs. Adv. Exp. Med. Biol. 2016, 928, 245–265. [PubMed]
98. Battle, T.E.; Arbiser, J.; Frank, D.A. The natural product honokiol induces caspase-dependent apoptosis in
B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005, 106, 690–697. [CrossRef] [PubMed]
99. Bi, L.; Yu, Z.; Wu, J.; Yu, K.; Hong, G.; Lu, Z.; Gao, S. Honokiol inhibits constitutive and inducible STAT3
signaling via PU.1-induced SHP1 expression in acute myeloid leukemia cells. Tohoku J. Exp. Med. 2015, 237,
163–172. [CrossRef] [PubMed]
100. Ishitsuka, K.; Hideshima, T.; Hamasaki, M.; Raje, N.; Kumar, S.; Hideshima, H.; Shiraishi, N.; Yasui, H.;
Roccaro, A.M.; Richardson, P.; et al. Honokiol overcomes conventional drug resistance in human multiple
myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005, 106, 1794–1800.
[CrossRef] [PubMed]
101. Ishikawa, C.; Arbiser, J.L.; Mori, N. Honokiol induces cell cycle arrest and apoptosis via inhibition of survival
signals in adult T-cell leukemia. Biochim. Biophys. Acta 2012, 1820, 879–887. [CrossRef] [PubMed]
102. Zhou, B.; Li, H.; Xing, C.; Ye, H.; Feng, J.; Wu, J.; Lu, Z.; Fang, J.; Gao, S. Honokiol induces proteasomal
degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.
Biochem. Pharmacol. 2017, 128, 12–25. [CrossRef] [PubMed]
103. Van den Berghe, W.; Sabbe, L.; Kaileh, M.; Haegeman, G.; Heyninck, K. Molecular insight in the
multifunctional activities of Withaferin A. Biochem. Pharmacol. 2012, 84, 1282–1291. [CrossRef] [PubMed]
104. Yco, L.P.; Mocz, G.; Opoku-Ansah, J.; Bachmann, A.S. Withaferin A inhibits STAT3 and induces tumor cell
death in neuroblastoma and multiple myeloma. Biochem. Insights 2014, 7, 1–13. [CrossRef] [PubMed]
105. Turkson, J.; Ryan, D.; Kim, J.S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A.D.;
Jove, R. Phosphotyrosyl peptides block STAT3-mediated DNA binding activity, gene regulation, and cell
transformation. J. Biol. Chem. 2001, 276, 45443–45455. [CrossRef] [PubMed]
106. Turkson, J.; Kim, J.S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A.D.; Jove, R.
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and
biological activity. Mol. Cancer Ther. 2004, 3, 261–269. [PubMed]
Cancers 2018, 10, 327 16 of 17
107. Hillion, J.; Belton, A.M.; Shah, S.N.; Turkson, J.; Jing, N.; Tweardy, D.J.; Di Cello, F.; Huso, D.L.;
Resar, L.M. Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet
oligonucleotides blocks tumor growth in HMGA1 transgenic model of t-cell leukemia. Leuk. Lymphoma 2014,
55, 1194–1197. [CrossRef] [PubMed]
108. Hong, D.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; Zhou, T.; Schmidt, J.;
Jo, M.; et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of
clinical activity in lymphoma and lung cancer. Sci. Transl. Med. 2015, 7, 314ra185. [CrossRef] [PubMed]
109. Turkson, J.; Zhang, S.; Mora, L.B.; Burns, A.; Sebti, S.; Jove, R. A novel platinum compound inhibits
constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem.
2005, 280, 32979–32988. [CrossRef] [PubMed]
110. Alas, S.; Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3)
activity in B-Non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop
and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001, 61, 5137–5144.
[PubMed]
111. Heinrich, P.C.; Behrmann, I.; Haan, S.; Hermanns, H.M.; Muller-Newen, G.; Schaper, F. Principles of
interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374, 1–20. [CrossRef]
[PubMed]
112. Verstovsek, S.; Kantarjian, H.; Mesa, R.A.; Pardanani, A.D.; Cortes-Franco, J.; Thomas, D.A.; Estrov, Z.;
Fridman, J.S.; Bradley, E.C.; Erickson-Viitanen, S.; et al. Safety and efficacy of INCB018424, a JAK1 and JAK2
inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363, 1117–1127. [CrossRef] [PubMed]
113. Wilks, A.F. The JAK kinases: Not just another kinase drug discovery target. Semin. Cell Dev. Biol. 2008, 19,
319–328. [CrossRef] [PubMed]
114. Santos, F.P.; Kantarjian, H.M.; Jain, N.; Manshouri, T.; Thomas, D.A.; Garcia-Manero, G.; Kennedy, D.;
Estrov, Z.; Cortes, J.; Verstovsek, S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in
patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115,
1131–1136. [CrossRef] [PubMed]
115. Kasper, S.; Breitenbuecher, F.; Hoehn, Y.; Heidel, F.; Lipka, D.B.; Markova, B.; Huber, C.; Kindler, T.; Fischer, T.
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and
is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Leuk. Res. 2008, 32, 1698–1708.
[CrossRef] [PubMed]
116. Burger, R.; Le Gouill, S.; Tai, Y.T.; Shringarpure, R.; Tassone, P.; Neri, P.; Podar, K.; Catley, L.; Hideshima, T.;
Chauhan, D.; et al. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human
myeloma cells in vitro and in vivo. Mol. Cancer Ther. 2009, 8, 26–35. [CrossRef] [PubMed]
117. Herrmann, A.; Vogt, M.; Monnigmann, M.; Clahsen, T.; Sommer, U.; Haan, S.; Poli, V.; Heinrich, P.C.;
Muller-Newen, G. Nucleocytoplasmic shuttling of persistently activated STAT3. J. Cell Sci. 2007, 120,
3249–3261. [CrossRef] [PubMed]
118. Mahipal, A.; Malafa, M. Importins and exportins as therapeutic targets in cancer. Pharmacol. Ther. 2016, 164,
135–143. [CrossRef] [PubMed]
119. Shuai, K.; Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3,
900–911. [CrossRef] [PubMed]
120. Shuai, K.; Liu, B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev.
Immunol. 2005, 5, 593–605. [CrossRef] [PubMed]
121. Krebs, D.L.; Hilton, D.J. Socs proteins: Negative regulators of cytokine signaling. Stem Cells 2001, 19, 378–387.
[CrossRef] [PubMed]
122. Talpaz, M.; Shah, N.P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O’Brien, S.; Nicaise, C.;
Bleickardt, E.; et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N. Engl. J.
Med. 2006, 354, 2531–2541. [CrossRef] [PubMed]
123. Listed, N. Gleevec (STI-571) for chronic myeloid leukemia. Med. Lett. Drugs Ther. 2001, 43, 49–50.
124. Ajayi, S.; Becker, H.; Reinhardt, H.; Engelhardt, M.; Zeiser, R.; Von Bubnoff, N.; Wasch, R. Ruxolitinib. Recent
Results Cancer Res. 2018, 212, 119–132. [PubMed]
Cancers 2018, 10, 327 17 of 17
125. Pemmaraju, N.; Kantarjian, H.; Kadia, T.; Cortes, J.; Borthakur, G.; Newberry, K.; Garcia-Manero, G.;
Ravandi, F.; Jabbour, E.; Dellasala, S.; et al. A phase I/II study of the janus kinase (JAK)1 and 2 inhibitor
ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin. Lymphoma Myeloma Leuk.
2015, 15, 171–176. [CrossRef] [PubMed]
126. Beebe, J.D.; Liu, J.-Y.; Zhang, J.-T. Two decades of research in discovery of anticancer drugs targeting STAT3,
how close are we? Pharmacol. Ther. 2018. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
